Assessment of HHV-6 and HHV-7 in patients after kidney transplantation by Folkmane, Inese et al.
INTRODUCTION
Human herpesviruses (HHV)-6 and -7 belong to the Beta-
herpesvirinae subfamily and are closely related to another
member of the subfamily, cytomegalovirus (CMV). Infec-
tion with HHV-6 and HHV-7 commonly occurs in child-
hood and then subsequently results in life-long latency such
that the seroprevalence rate in adults is over 90% (Yaman-
ishi, 2001).
Primary HHV-6 infection has been associated with febrile
illness, including exanthem subitum and infection, which
are most likely transmitted by means of saliva. The infec-
tion usually occurs during the first two years of life. The vi-
rus uses CD46 as a cellular receptor and therefore HHV-6
may also infect other cell types, such as monocytes, epithe-
lial and endothelial cells (Santoro et al., 1999). The clinical
course of primary HHV-6 infection is generally benign and
self-limited. However, several severe complications have
been reported, including encephalitis/encephalopathy, hepa-
titis and thrombocytopenia (Yoshikawa, 2003). Infection
with HHV-7 is also widespread in the population, with pri-
mary infection occurring early in life, probably through
salivary transmission. HHV-7 has also been associated with
febrile illness in children and is another etiologic agent of
exanthem subitum (Tanaka et al., 1994). The virus uses
CD4 as a cellular receptor to infect T cells (Lusso et al.,
1994).
In adult solid organ transplant recipients, while primary in-
fection is uncommon, reactivation of endogenous latent vi-
ruses seems to occur very frequently with infection rates of
30–50% reported in studies (Mendez et al., 2001; Ra-
zonable et al., 2005). The stimulus for reactivation of beta-
herpesviruses is an immunosuppressive (IS) regimen in re-
nal transplant (RT) recipients. However, these viruses pos-
sess immunomodulating properties, including the ability to
alter the expression of immune activation molecules, modu-
late expression of several cytokines and chemokines and in-
duce apoptosis in lymphocytes, which may contribute to
immunosuppression. Productive infection of CD4 T-cells
results in cytopathic effects and cell destruction (Lusso,
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Human herpesviruses HHV-6 and HHV-7 reactivation in transplantation is associated with indirect
immunomodulatory effects, such as cytomegalovirus (CMV) disease, increased opportunistic in-
fections, graft dysfunction and acute rejection (AR). In this study, we analysed the clinical and im-
munological outcomes in renal transplant recipients (RTR) with active HHV-6 and HHV-7
infection. Between January 2007 and December 2007, clinical, virological and immunological
tests were carried out in 46 RTR. The patients were divided into three groups: with active HHV-6
infection; with active HHV-7 infection; and without infection (control). The mean follow-up was
14 ± 2.5 months. At three months after renal transplantation (RT), active CMV infection was pres-
ent in 12 (26%); HHV-6 in four (8.6%); and HHV-7 in nine (19.5%) of RTR. Active ß-herpes-
viruses infection was not associated with more frequent AR and worsening of graft function in
recipients at different times after RT. The lymphocyte subsets (CD3+; CD4+ and CD8+ cell count)
were considerably lower in RTR before RT. At 3 months after RT CD19+ and CD25+ cell counts
were significantly increased in the HHV-7 group compared with the control group (P < 0.05). Sig-
nificant differences were not found in clinical and immunological outcomes between patients with
active ß-herpesviruses infection and those without active ß-herpesviruses infection.
Key words: human herpes virus, immunosuppression, renal transplantation, viral infections, lym-
phocyte subsets.
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2006). It has been suggested that the HHV-6 infection and
activation result in clinical symptoms, including fever, skin
rash, interstitial pneumonitis, bone marrow suppression, en-
cephalitis, and rejection (Snydman et al., 2001). In contrast
to studies of HHV-6 infection in organ-transplant recipients,
the number of studies examining HHV-7 infection in RT
patients is limited. According to several recent studies,
HHV-7 may act as a co-factor for CMV activation and
CMV disease development in organ-transplant recipients
(Osman et al., 1996).
A growing body of evidence suggests that the major impact
of HHV-6 and HHV-7 reactivation in transplantation is re-
lated to indirect immunomodulatory effects, such as their
association with CMV disease, increased opportunistic in-
fections, graft dysfunction and rejection (Mendez et al.,
2001; Chapenko et al., 2009).
In the present study we estimated the prevalence of latent
and active HHV-6 and HHV-7 infection and the association
of this infection with clinical and immunological parameters
of graft outcome in renal transplant recipients.
MATERIALS AND METHODS
Fifty recipients receiving transplants at the Latvian Trans-
plant Centre between January 2007 and December 2007 and
27 deceased renal allograft donors were included in this
prospective study. The mean follow-up was 14 ± 2.5
months. Four early graft losses (until three months) oc-
curred due to arterial graft thrombosis (n = 1) and death (n =
3). The causes of death were surgical peritonitis, pulmonary
embolism, and one unknown cause as the patient was lost
during follow up. Thus, further clinical, virological data and
immunological tests were carried out in 46 of the 50 pa-
tients at 12 months. EDTA blood samples were collected
from the patients before transplantation, at two weeks, and
3, 6 and 12 months after transplantation.
Nested polymerase chain reaction (nPCR) was used for the
detection of viral genomic sequences in DNA isolated from
peripheral blood leukocytes (PBL) and plasma (markers of
latent/persistent and active infection, respectively). DNA
was isolated from whole blood using the phenol-chloroform
method. The QIAamp DNA Blood Mini Kit was used to ex-
tract DNA from plasma. -globin PCR was applied to check
DNA quality. The corresponding primer pairs were used for
the detection of CMV, HHV-6 and HHV-7 genomic se-
quences (Secchiero et al., 1995, Berneman et al., 1992;
Studahl et al., 1995) in DNA isolated from whole blood and
plasma. To exclude the possibility of contamination during
the PCR, HHV-6 and HHV-7 negative DNA, as well as wa-
ter controls, were included in each experiment. The amplifi-
cation products were visualised in 1.7% agarose gel with
ethidium bromide staining and analysed using the Kodak
Electrophoresis Documentation and Analysis System
(EDAS) 290 ASV.
Restriction endonuclease analysis was carried out using en-
zyme HindIII for the detection of HHV-6 virus variants.
This enzyme cuts HHV-6B 163 kbp amplimer into two
fragments: 66 and 97 kbp and does not cut HHV-6A
amplimer. In this way, HHV-6A and HHV-6B virus vari-
ants were distinguished.
The concentrations of lymphocyte subsets (CD3+, CD4+,
CD8+, CD4+/CD8+, CD19+ and CD25+ in 1 mm3 of
blood) were measured using a flow cytometer (Becton&
Dickinson). The numbers of total lymphocytes in each cell
subset were expressed as absolute counts.
Clinical parameters (immunosuppressive regimens, acute
rejection episodes, transplant function and late complica-
tions) were obtained through medical records.
Initial immunosuppression in all patients consisted of cyclo-
sporine (CsA), mycophenolate mofetil (MMF) and
prednisolone (P) and induction with monoclonal anti-CD25
antibodies (Basilixibam/Daclizumab). Maintenance immu-
nosuppression consisted of CsA, MMF and P. Treatment
with oral CsA in microemulsion was started before surgery
(10 mg/kg/d) to obtain therapeutic CsA blood levels and
then was adjusted, based on a target level of 150–250 ng/ml
during the first four weeks and 150–200 ng/ml thereafter.
The maintenance dose of orally administered MMF was
1.0–2.0 g/d. Methylprednisolone 5.0 mg/kg/d was adminis-
tered on three consecutive days from the day of RT. Oral
prednisolone was started on the first day after operation at
0.5 mg/kg/d and reduced gradually till 5.0–10 mg/d.
Acute rejection (AR) episodes were diagnosed on the basis
of characteristic clinical features and were confirmed by
percutaneous biopsy. The histological features were graded
according to the Banff 2005 classification. AR episodes
were treated with intravenous methylprednisolone at 500
mg/d for three consecutive days. Steroid resistant cases
were treated with anti-thymocyte globulin (ATG) at
4 mg/kg for 7–10 days.
Statistical analysis. Data were expressed as means and
standard deviations. Statistical differences between groups
were assessed by analysis of variance (ANOVA) or Chi-
square and t-test. A P-value < 0.05 was considered statisti-
cally significant.
The study was performed in accordance with the permission
of the Local Ethics Committee and all the participants gave
informed consent before the examination.
RESULTS
Latent/persistent ß-herpesviruses infection was detected in
23 of 27 (85%) transplant donors. CMV infection was
found in seven (26%), HHV-6 in five (18.5%) and HHV-7
infection in 19 (70%) of donors. Active ß-herpesviruses in-
fection occurred in four (15%) donors and of them two
(7.5%) had active CMV and 2 had active HHV-7 infection.
ß-herpesviruses genomic sequence detection in PBL DNA
samples of the 50 recipients before RT identified latent/per-
sistent CMV infection in five (10%), HHV-6 in ten (20%)
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and HHV-7 infection in 39 (78%). At three months after RT
active ß-herpesviruses infection (plasma viremia) was de-
tected in 27 of 46 (58.7%) recipients, including twelve
(26%) CMV, four (8.6%) HHV-6, nine (19.5%) HHV-7 and
two (4.3%) dual HHV-6 and HHV-7 infection cases. To
analyze the different clinical and immunological outcomes
in patients with active HHV-6 and HHV-7 infection, the re-
cipients were divided into three groups: Group I, with active
HHV-6 infection (n = 4); Group II, with active HHV-7 in-
fection (n = 9) and Group III (control) without active infec-
tion (n = 31). Two patients with dual active ß-herpesviruses
infection were excluded due to small sample size.
Demografic and clinical data on recipients with and without
active ß-herpesviruses infection are given in Table 1. The
three patient groups showed no significant differences in
demographic parameters. The incidence of acute CMV in-
fection and AR did not significantly differ between the pa-
tients who developed active ß-herpesviruses infection and
those who did not. Interestingly, patients without active
ß-herpesviruses infection showed a higher rate of acute
CMV infection (29%) compared to patients in the group
with active HHV-6 (0%) and HHV-7 (11.1%), respectively.
Compared with the control group (32%), AR rate was
slightly higher in patients with active HHV-6 infection
(50%), but again, without statistical significance. There was
also no significant difference in graft function at 3 and 12
months among the groups. The mean serum creatinine at 12
months was even lower in patients with active HHV-7 than
in the control group (0.11 vs 0.13, P > 0.05).
Table 2 gives the numbers of lymphocytes in subsets in the
peripheral blood of control group patients with latent/persis-
tent infection compared with the numbers of cells detected
in the patients with active HHV-6 and HHV-7 infection at
different times after RT.
Counts of CD3+, CD4+ and CD8+ cells were considerably
lower before RT, but no significant changes between the
three groups were found. Also, there were no significant
changes in CD4+/CD8+; CD19+ and CD25+ counts in the
study groups. At three months after RT, higher CD3+ and
CD4+ cell counts were observed only in the HHV-7 group
compared to control group (1.14 vs 0.73, P > 0.05 and 0.59
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T a b l e 1
MAIN DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF THE PATIENTS INCLUDED IN THE STUDY







Acute CMV infection incidence (at 3 months)
Acute rejection incidence









































HHV-6 and HHV-7, human herpesviruses; *P controls versus group I; **P controls versus group II
T a b l e 2
LYMPHOCYTE COUNTS BY SUBSETS IN RECIPIENTS WITH LATENT/PERSISTENT AND ACTIVE ß-HERPESVIRUSES INFECTION











































































RT, renal transplant; HHV-6 and HHV-7, human herpesviruses
vs 0.37, P > 0.05, respectively). Compared with the control
group, the HHV-7 group had significantly increased CD19+
and CD25+ cell counts (P < 0.05 and P < 0.05, respec-
tively).
DISCUSSION
Our study was hindered by the small study groups, which
resulted in lack of statistical significance for many parame-
ters. Consistent with our previous studies, we found high in-
cidence of latent/persistent CMV, HHV-6 and HHV-7 in-
fection in renal donors and recipients (26%; 18.5%; 70%
and 10%; 20% and 78%, respectively). In contrast to our
previous studies, a lower overall rate of active CMV,
HHV-6 and HHV-7 infection was found in this study (26%;
19.5% and 4.3%, respectively). This may be due to the
more intensive prophylaxis with valganciclovir used in re-
cent years. We did not find significant association between
active ß-herpesviruses infection and AR and graft function
in recipients at different times after RT. The CD3+; CD4+
and CD8+ cell counts were considerably lower before RT,
indicating impaired cellular immune function in patients
with end-stage renal failure. Secondary immune failure in
uremia is multi-faceted and is influenced by uremic intoxi-
cation per se, by altered renal metabolism of immunologi-
cally active proteins and by specific effects of renal replace-
ment therapy (Girndt et al., 1999). Interestingly, CD19+
and CD25+ cell counts were significantly higher in the
HHV-7 group compared with the control group three
months after RT (P < 0.05 and P > 0.05, respectively). It is
possible that increase in expression of CD19+ and CD25+
cells in the HHV-7 group may be caused by down-regula-
tion of cellular and humoral immune response due to viral
indirect immunomodulatory effects (Lusso et al., 1994;
Lusso, 2006; Mendez et al., 2001). On the other hand, a
normal or slightly lower overall lymphocyte subset count
and relatively low rate of complications after RT suggests
that the maintenance IS regimen with CsA, MMF and P
does not induce over-immunosuppression in patients after
RT.
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HHV-6 UN HHV-7 NOVÇRTÇÐANA PACIENTIEM PÇC NIERES TRANSPLANTÂCIJAS
Cilvçka herpesvîrusu – 6 (HHV-6) un 7 (HHV-7) reaktivâcija pçc transplantâcijas visbieþâk ir saistîta ar virkni imûnmodulçjoðo efektu:
citomegalovîrusa (CMV) infekcijas aktivâciju, oportûnistisko infekciju pieaugumu, transplantâta disfunkciju un akûtu transplantâta
atgrûðanu. Ðajâ pçtîjumâ tika analizçtas klîniskâs un imunoloìiskâs konsekvences nieres transplantâta (NT) pacientiem ar aktîvu HHV-6 un
HHV-7 infekciju. Pçtîjumâ iekïauti 46 NT pacienti, kam laikâ no 2007. g. janvâra lîdz 2007. g. decembrim tika analizçti klîniskie,
virusoloìiskie un imunoloìiskie râdîtâji. Pacienti tika sadalîti trîs grupâs: pacienti ar aktîvu HHV-6 infekciju (I grupa), pacienti ar aktîvu
HHV-7 infekciju (II grupa) un pacienti bez aktîvas infekcijas (kontroles grupa). Vidçjais novçroðanas laiks bija 14 ± 2,5 mçneði. Trîs
mçneðus pçc NT aktîva CMV infekcija tika atklâta divpadsmit (26%) pacientiem, HHV-6 – èetriem (8.6%) pacientiem, bet HHV-7 –
deviòiem (19.5%) pacientiem. Netika atklâta aktîvas ß-herpesvîrusu infekcijas asociâcija ar akûtu transplantâta atgrûðanu un/vai
transplantâta disfunkciju daþâdos laika periodos pçc NT. Ievçrojami samazinâtas CD3+; CD4+ un CD8+ limfocîtu subpopulâcijas bija tikai
pirms NT. Trîs mçneðus pçc NT CD19+ un CD25+ ðûnu skaits bija ievçrojami augstâks pacientiem ar aktîvu HHV-7 infekciju nekâ
kontroles grupâ (P < 0.05). Pçtîjumâ netika atklâtas nozîmîgas atðíirîbas klîniskajos un imunoloìiskajos râdîtâjos pacientiem ar vai bez
aktîvas ß-herpesvîrusu infekcijas.
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